Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US Biosimilar Fee Collections Fall Short

The FDA Has Modified Its Carryover Spend-Down Plan

Oct 10 2019

• By Sue Sutter

Road_Slow — US FDA's plan for spending down its biosimilar user fee carryover balance unexpectedly accelerated in FY 2018, forcing the agency to readjust. • Source: Shutterstock

Related Content

The Big Spend-Down: US FDA Eyes $159M Reduction In Carryover User Fees

Apr 08 2018

Biosimilar User Fee Forecast: Unchanged Or Lower In FY 2019, US FDA Says

Jul 31 2018

US FDA Biosimilar User Fee Collections, Expenditures Hit A High Point In 2017

May 29 2018

US FDA Reports Millions In Unpaid GDUFA Program Fees

Oct 07 2019

User Fee Delinquencies Rising At US FDA After PDUFA Redesign

Oct 02 2019

Biosimilar User Fee Collections Drop Well Below Estimates, But US FDA Not Worried

Jun 10 2019

Biosimilars: Rise In US FDA Approvals Means Lower Or Flat User Fees In FY 2020

Aug 01 2019

US Biosimilars: FDA Seeks To Build On Record Number Of Approvals, But Shutdown May Blunt Progress

Jan 23 2019

Additional Topics

United States Regulation Biosimilars FDA BioPharmaceutical

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window